Pharmacodynamics (PD) and genomic profiling of pts treated with cabiralizumab (cabira) plus nivolumab (NIVO) provide evidence of on-target tumor immune modulations and support future clinical applications.

被引：8

作者：

Carleton, Michael

Powers, Janine

Phillips, Penny

Beg, Muhammad Shaalan

Lee, James J.

Rahma, Osama E.

Piha-Paul, Sarina Anne

Lee, Ernestine

Hestir, Kevin

Xu, Ke

Pandya, Dimple

Inamdar, Sandeep P.

Perna, Serena K.

Huang, Shih-Min A.

Wainberg, Zev A.

机构：

[1] Bristol Myers Squibb Co, Princeton, NJ USA

[2] FivePrime Therapeut, San Francisco, CA USA

[3] Univ Texas Southwestern Med Ctr Dallas, Dallas, TX 75390 USA

[4] Univ Pittsburgh, Canc Inst, Pittsburgh, PA USA

[5] Harvard Med Sch, Dana Farber Canc Inst, Boston, MA 02115 USA

[6] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[7] Univ Calif Los Angeles, Sch Med, Dept Med, Los Angeles, CA 90024 USA

来源：

关键词：

D O I：

10.1200/JCO.2018.36.15_suppl.3020

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

3020

引用

页数：2